Latest / Breaking News To Trading Moves
The GLP-1 Shift: Hims & Hers Market Evolution
Hims and Hers misses revenue estimates as GLP-1 strategy shift pressures margins
Hims and Hers Health is back in focus after missing first-quarter revenue estimates and posting a surprise loss, even though the company raised its full-year revenue forecast. The key issue is not simply demand. The bigger story is the business model shift. Hims is moving away from lower-cost compounded GLP-1 weight-loss drugs and toward branded, FDA-approved treatments such as Wegovy through its partnership with Novo Nordisk. That shift may support long-term credibility, but it also brings margin pressure, legal…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.